7 Or 8 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.7)
-
Publication number: 20130004478Abstract: The present invention is directed to a hemostatic or tissue sealing material having (a) a peptide having a sequence SEQ ID NO: 1 or an amino acid analog sequence thereof, and (b) a scaffold for said peptide or amino acid analogue sequence. The scaffold is preferably hemostatic, such as a natural or genetically engineered absorbable polymer, a synthetic absorbable polymer, or combinations thereof. The natural or genetically engineered absorbable polymers can be selected from the group consisting of a protein, a polysaccharide, or combinations thereof.Type: ApplicationFiled: June 30, 2011Publication date: January 3, 2013Inventors: Yi-Lan Wang, Guanghui Zhang
-
Publication number: 20120328666Abstract: Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.Type: ApplicationFiled: August 26, 2011Publication date: December 27, 2012Applicant: Unigene Laboratories Inc.Inventors: Nozer M. Mehta, William Stern, James P. Gilligan
-
Publication number: 20120329730Abstract: The disclosure provides aromatic-cationic peptide compositions and methods of preventing or treating disease using the same. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.Type: ApplicationFiled: January 24, 2011Publication date: December 27, 2012Inventors: Hazel H. Szeto, Peter W. Schiller
-
Publication number: 20120329729Abstract: The present invention provides methods and pharmaceutical formulations for treating diabetic foot ulcers.Type: ApplicationFiled: May 9, 2012Publication date: December 27, 2012Applicant: UNIVERSITY OF SOUTHERN CALIFORNIAInventors: Kathleen E. Rodgers, Gere S. diZerega
-
Publication number: 20120321701Abstract: The application provides Ang-(1-7) receptor agonist peptides and their use for treating acute lung injury.Type: ApplicationFiled: August 21, 2012Publication date: December 20, 2012Applicant: CHARITÉ-UNIVERSITÄTSMEDIZIN BERLINInventors: Thomas Walther, Wolfgang Kuebler
-
Publication number: 20120322724Abstract: The invention provides conjugates, comprising an organ, tissue or tumor cell homing molecule linked to a moiety. Such a moiety can be, for example, an oligonucleotide, small interfering RNA, gene, virus, protein, pharmaceutical or detectable agent. In addition the invention provides methods to diagnose or treat a pathology of the muscle or heart, by administrating to a subject having or suspected of having a pathology a molecule or conjugate that homes to, binds to and is taken up by the muscle cells or heart cells.Type: ApplicationFiled: August 7, 2012Publication date: December 20, 2012Applicant: Prosensa Technologies B.V.Inventors: Johannes Antonius Heemskerk, Judith Christina Theodora Van Deutekom, Petra Van Kuik-Romeijn, Gerard Johannes Platenburg
-
Patent number: 8334364Abstract: [Problems] A derivative of a nucleic acid antimetabolite is demanded which can show a high therapeutic effect at a low dose. [Means For Solving Problems] Disclosed is a high molecular weight derivative of a nucleic acid antimetabolite, which is characterized by comprising a high molecular weight compound comprising a polyethylene glycol moiety and a polymer moiety having a carboxyl group in a side chain and a nucleoside derivative which can act as a nucleic acid antimetabolite, wherein the carboxyl group in the side chain is bound to a hydroxyl group in the nucleoside derivative via an ester bond. Also disclosed is a method for producing the high molecular weight derivative.Type: GrantFiled: November 1, 2007Date of Patent: December 18, 2012Assignee: Nipon Kayaku Kabushiki KaishaInventors: Keiichiro Yamamoto, Kazutoshi Takashio
-
Patent number: 8329144Abstract: A peptide analogue which is not more than 50 amino acids in length, and which is capable of being recognized by a T cell receptor that recognizes an epitope comprising sequence 62PQPELPY68 (SEQ ID NO:1), and fusion proteins, pharmaceutical compositions, and kits comprising the same, are provided herewith. Also provided are methods of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising contacting a sample from the individual with a peptide analogue and determining in vitro whether T cells in the sample recognize the peptide analogue.Type: GrantFiled: November 3, 2006Date of Patent: December 11, 2012Assignee: Isis Innovation LimitedInventors: Robert Paul Anderson, Adrian Vivian Sinton Hill, Derek Parry Jewell
-
Patent number: 8324170Abstract: A method of inhibiting apoptosis in a cell includes administering to a cell an effective amount of a cell penetrating peptide (CPP), wherein the CPP consists of about 5 to about 41 amino acids and is substantially homologous to a portion of the C-terminal region of IFN?R2.Type: GrantFiled: August 9, 2010Date of Patent: December 4, 2012Assignee: Case Western Reserve UniversityInventor: Shigemi Matsuyama
-
Patent number: 8324166Abstract: This invention relates to NAP-like and SAL-like peptide mimetics, polypeptides, or small molecules derived from them, and their use in the treatment of neuronal dysfunction, neurodegenerative disorders cognitive deficits, neuropsychiatric disorders, and autoimmune disease.Type: GrantFiled: February 18, 2010Date of Patent: December 4, 2012Assignees: Ramot at Tel-Aviv University, Ltd., Allon Therapeutics, Inc.Inventors: Illana Gozes, Alistair Stewart, Maya Maor, Sharon Furman-Assaf
-
Patent number: 8324344Abstract: Isolated polypeptides, nucleic acids, and methods relating to cellular internalization of materials are described herein. Generally, the isolated polypeptides include a membrane transduction domain of human tissue factor pathway inhibitor-2 (TFPI-2). In some cases, the isolated polypeptide can be a fusion peptide that includes a membrane transduction domain of human TFPI-2 and a heterologous peptide domain. The nucleic acids include nucleic acids that encode the isolated polypeptides described herein. The methods generally include providing a composition that includes a membrane transduction domain of human TFPI-2 coupled to a material, and contacting the composition with a cell under conditions effective to permit the cell to internalize the composition.Type: GrantFiled: October 7, 2009Date of Patent: December 4, 2012Assignee: STC.UNMInventor: Walter Kisiel
-
Patent number: 8318681Abstract: A method of using proteins of the SIRT family or of polypeptide or peptide fragments of SIRT proteins as an active ingredient for slimming, alone or in combination with at least one other active agent, in a cosmetic composition or for the preparation of a pharmaceutical and/or dermatological composition is described. Said peptides are intended, in particular, for treatment of cellulite and/or used to decrease, eliminate or prevent excess fat beneath the skin.Type: GrantFiled: July 7, 2011Date of Patent: November 27, 2012Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Publication number: 20120294801Abstract: Conjugates of porphyrin, chlorophyll and bacteriochlorophyll photosensitizers with RGD-containing peptides or RGD peptidomimetics are provided that are useful for photodynamic therapy (PDT), particularly vascular-targeted PDT (VTP), of tumors and nonneoplastic vascular diseases such as age-related macular degeneration, and for diagnosis of tumors by different techniques.Type: ApplicationFiled: April 16, 2012Publication date: November 22, 2012Applicant: Yeda Research and Development Co., Ltd.Inventors: Avigdor Scherz, Yoram Salomon, Efrat Rubinstein, Alexander Brandis, Doron Eren, Karin Neimann
-
Publication number: 20120289454Abstract: It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a “ligand moiety”) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a “metallodrug” or “metallotherapeutic.” The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.Type: ApplicationFiled: May 12, 2012Publication date: November 15, 2012Applicant: METALLOPHARM LLCInventors: James A. Cowan, Ada S. Cowan, Donna T. Palmer
-
Patent number: 8309513Abstract: The present invention relates to the use of an antisecretory protein or a derivative, homologue, and/or fragment thereof, having antisecretory activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of compartment syndrome. A compartment syndrome may be caused by or a cause of a variety of other conditions which are also encompassed by the present invention, such as viral and bacterial infections. Furthermore, the invention relates to a method for the treatment and/or prevention of compartment syndrome in a mammal in need thereof.Type: GrantFiled: October 27, 2008Date of Patent: November 13, 2012Assignee: Lantmannen As-Faktor ABInventors: Hans-Arne Hansson, Stefan Lange, Eva Jennische, Tomas Bergström
-
Patent number: 8304393Abstract: It is intended to provide a novel oligopeptide which can be relatively easily produced, has not only a hair growth-stimulating effect but also an effect of promoting the growth of epithelial cells (for example, skin regeneration) and can easily pass through the horny layer to thereby reach the desired target cells in which its effects are to be exerted. Namely, water-soluble oligopeptides containing a proryl isoleucyl glycyl unit or an isoleucyl glycyl serine unit and having from 3 to 7 amino acids and water-soluble salts thereof.Type: GrantFiled: May 3, 2010Date of Patent: November 6, 2012Assignee: Patent Technology Development Inc.Inventors: Syuichi Oka, Akinori Tsuruda, Yasuhiro Kawano, Mitsuo Suzuki, Satoshi Nakazato
-
Publication number: 20120270783Abstract: Rapid opioid detoxification procedures are provided which include sedating a patient with an anesthetic agent having a short full recovery period. The patient is administered an opioid antagonist while sedated and can be revived to an ambulatory condition within eight hours of initiating therapy. The described methods for detoxification also include administering a diarrhea suppressant, such as octreotide acetate, to limit this unfortunate side effect of the detoxification.Type: ApplicationFiled: April 21, 2011Publication date: October 25, 2012Inventor: Lance L. Gooberman
-
Publication number: 20120270811Abstract: A series of peptides with divergent confirmations including structures of formula (1A), (1B), (2) and (3) are provided. In the formula, wherein U, G, A, B, R1, R2 and T are as defined in the specification. The divergent peptides disclosed in the present invention are characterized in a mineral binding affinity function.Type: ApplicationFiled: October 21, 2011Publication date: October 25, 2012Applicant: KAOHSIUNG MEDICAL UNIVERSITYInventors: Hui-Ting Chen, Kuang-Chan Hsieh, Je-Ken Chang, Gwo-Jaw Wang, Yin-Chih Fu, Mei-Ling Ho, Cherng-Chyi Tzeng
-
Publication number: 20120270795Abstract: The present invention relates to the field of protein misfolding diseases and thus to diseases which are associated with or induced by abnormal or pathogenic three-dimensional folding of proteins and/or peptides or which are linked to pathogenic conformational changes of proteins and/or peptides, such as Alzheimer's disease. Particularly, the present invention provides novel trimeric pyrazole compounds, which exhibit a therapeutic effectiveness in regard to the aforementioned protein misfolding diseases, and refers to their use for the treatment of such protein misfolding diseases, especially neurodegenerative diseases as well as to medicaments or pharmaceutical compositions comprising these compounds.Type: ApplicationFiled: January 26, 2010Publication date: October 25, 2012Inventors: Thomas Schrader, Katrin Hochdörffer, Julia März-Berberich, Luitgard Nagel-Steger, Gal Bitan, Sharmistha Sinha
-
Publication number: 20120270808Abstract: Embodiments of the invention include methods for selecting in parallel (i.e., synchronously or simultaneously) peptides that target a number of organs, in which each peptide targets distinct tissues or organs. Typically, the methods of the invention provide for peptide selection in a Minimal number of subjects and still provides a selectively binding peptide. In certain aspects, methods of identifying peptides that bind to multiple selected tissues or organs of an organism may comprise the steps of administering a phage display library to a first subject; obtaining a sample of two or more selected tissues; obtaining phage displaying peptides that bind to the samples from the first subject; enriching for peptides by administering phage isolated from the samples of the first subject to a second subject; obtaining a sample of two or more selected tissues from the second subject; and identifying the peptides displayed.Type: ApplicationFiled: April 4, 2012Publication date: October 25, 2012Inventors: Mikhail Kolonin, Wadih Arap, Renata Pasqualini
-
Publication number: 20120270812Abstract: The present invention relates to novel compounds as well as to compositions, methods, and kits comprising the compounds for determining an alkyltransferase (ATase), in particular an alkylguanine-DNA alkyl transferase (AGT). In general, the novel compounds provide for determining ATase levels, in particular for in vivo applications including, but not limited to, theranostic applications, in particular to cancer-related applications.Type: ApplicationFiled: August 24, 2010Publication date: October 25, 2012Applicant: Duke UniversityInventors: Michael R. Zalutsky, Ganesan Vaidyanathan
-
Publication number: 20120269772Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: ApplicationFiled: June 29, 2012Publication date: October 25, 2012Applicant: Camurus ABInventors: Krister THURESSON, Fredrik TIBERG, Markus JOHANSSON, Ian HARWIGSSON, Fredrik JOABSSON, Markus JOHNSSON
-
Patent number: 8288341Abstract: Methods of treating radiation injury of a subject in need thereof comprising administering to the subject a peptide consisting of an amino acid molecule selected from the group consisting of VVC, LAG, AQG, LQGV, QVVC, MTRV, LAGV, LQAV, PGCP, VGQL, RVLQ, EMFQ, AVAL, FVLS, NMWD, LCFL, FSYA, FWVD, AFTV, LGTL, QLLG, YAIT, APSL, ITTL, QALG, GVLC, NLIN, SPIE, LNTI, LHNL, CPVQ, EVVR, MTEV, EALE, EPPE, LGTL, VGGI, RLPG, LQGA, LCFL, TLAVE, VEGNL, LNEAL, CPRGVNP, MGGTWA, LTCDDP, VCNYRDV, QPLAPLVG, and DINGFLPAL. The invention provides for administration of the peptide prior to and following exposure of the subject to a source of radiation.Type: GrantFiled: July 15, 2009Date of Patent: October 16, 2012Assignee: Biotempt B.V.Inventors: Robbert Benner, Nisar Ahmed Khan, Richard Michael Carlton
-
Patent number: 8288334Abstract: The present invention relates to new peptides, pharmaceutical composition and cosmetic composition including them and their use for wound healing.Type: GrantFiled: June 14, 2010Date of Patent: October 16, 2012Assignee: Gene Signal International SAInventors: Salman Al-Mahmood, Sylvie Colin
-
Publication number: 20120258921Abstract: Peptides for the treatment of inflammation, and therapeutic uses and methods of using the same are disclosed. Peptides including a transducing sequence are effective for inhibiting cytokine activity and TNF-? secretion through interaction with toll-like receptor signaling pathways. Experiments are described illustrating the efficacy of the compounds in treating otitis media, noise-induced hearing loss, age-related hearing loss, and improvement of ordinary hearing.Type: ApplicationFiled: April 5, 2012Publication date: October 11, 2012Applicant: 13Therapeutics, Inc.Inventors: Sharon L. McCoy, Steven H. Hefeneider
-
Publication number: 20120252730Abstract: Peptides and cyclized analogs thereof that are useful as platelet aggregation inhibitors in the treatment of cardiac disease, including acute coronary syndrome are disclosed.Type: ApplicationFiled: September 2, 2010Publication date: October 4, 2012Applicant: UNIVERSITY OF CHICAGOInventors: Milan Mrksich, Juan Sanchez-Cortes
-
Publication number: 20120251453Abstract: Disclosed are conjugates comprising the annexin 1-binding peptide IFLLWQR covalently linked to a therapeutic or detectable agent. Also disclosed are compositions comprising a moiety and a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are isolated nucleic acids comprising a nucleic acid sequence encoding a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are methods comprising administering to a subject a composition comprising a moiety and a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell. Also disclosed are methods of targeting a tumor cell in a subject comprising administering to the subject a peptide comprising an amino acid sequence that can bind to a carbohydrate receptor on a cell.Type: ApplicationFiled: December 23, 2010Publication date: October 4, 2012Inventors: Michiko Fukuda, Kazuhiro Sugihara, Naohira Kanayama
-
Publication number: 20120252734Abstract: The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.Type: ApplicationFiled: June 15, 2012Publication date: October 4, 2012Inventors: Gary Lee Olson, Charles Michael Cook, Christopher Raymond Self
-
Publication number: 20120244192Abstract: The invention provides sustained release formulations comprising a C5a receptor antagonist. In certain embodiments the sustained-release formulations include microparticles that comprise a complement C5aR antagonist and a biodegradable polymeric matrix. Methods of treatment comprising the sustained release formulations of the invention are also provided.Type: ApplicationFiled: April 26, 2010Publication date: September 27, 2012Inventor: Gary P. Cook
-
Publication number: 20120245091Abstract: The present invention relates to a polypeptide derived from a highly conserved region (HCR) I-III of an extracellular region of a CD99 and CD99 family such as CD99L2 and PBDX (or XG), which are a kind of transmembrane protein, or a fused protein thereof. The polypeptide or the fused protein thereof has an activating function of inhibiting the extravasation of white blood cells, or inhibiting the growth and/or metastasis of cancer cells. The present invention also provides a polynucleotide coding the polypeptide, a vector including same, and a transformant transformed by the vector. In addition, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof for preventing or treating inflammatory diseases. Further, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof inhibiting the growth and/or metastasis of cancer cells, i.e., a pharmaceutical composition for preventing or treating cancer.Type: ApplicationFiled: August 24, 2010Publication date: September 27, 2012Applicant: SUPADELIXIR INC.Inventors: Jang-Hee Hahn, Kyoung-Jin Lee, Sun-Hee Lee, Hyun-Mi Ju
-
Publication number: 20120244136Abstract: The present invention relates to Cardiac Targeting Peptides or CTPs that are able to transduce cardiomyocytes specifically in culture and in vivo, and to methods for using such peptides and their derivatives to deliver peptides, proteins or nucleic acids specifically to the heart. It is based, at least in part, on the discovery that the peptide APWHLSSQYSRT (SEQ ID NO:1) functioned as a cardiac-specific protein targeting peptide and was successful in delivering a number of different cargoes to cardiac muscle cells in vitro and in vivo.Type: ApplicationFiled: October 14, 2011Publication date: September 27, 2012Inventors: Paul David Robbins, Maliha Zahid
-
Publication number: 20120245081Abstract: Exocyclic peptide mimetics that disable Fas were developed. A three dimensional model of the Fas receptor-ligand complex was constructed and structurally predicted regions of the receptor that were relevant to binding ligand were used to create constrained peptide mimetics. Exocyclic anti-Fas peptide mimetics were identified that block Fas receptor-ligand interactions, and modulate Fas biological activity both in vitro and in vivo. The mimetics are useful, e.g., for treating Fas-related pathologies.Type: ApplicationFiled: August 15, 2011Publication date: September 27, 2012Applicant: Trustees of the University of PennsylvaniaInventors: Mark I. Greene, Ramachandran Murali, Akihiro Hasegawa
-
Patent number: 8273710Abstract: Disclosed is a protein hydrolysate having DPP-IV inhibiting activity, the hydrolysate being enriched in peptides having a length of 2-8 amino acids comprising at least one proline residue, an isolated peptide derivable from such a protein hydrolysate, or a mixture thereof, and the use of such protein hydrolysate or isolated peptide for the manufacture of a medicament, food supplement, beverage or food product for prophylaxis and/or treatment of a DPP-IV mediated condition, in particular chosen from the group of obesity, type 2 diabetes mellitus and an immunological disorder.Type: GrantFiled: November 30, 2005Date of Patent: September 25, 2012Assignee: Campina Nederland Holding B.V.Inventor: Jan-Willem Pieter Boots
-
Publication number: 20120238503Abstract: The present invention relates to human laminin ?2 chain LG3 domain and active peptides promoting cell adhesion, spreading, migration, and neurite outgrowth. More particularly, it was found that when nerve cells are incubated using human laminin ?2 chain LG3 domain and active peptides in the LG3 domain, cell adhesion, spreading, migration, and neurite outgrowth of nerve cells promote and the promotion of cell adhesion, spreading, migration, and neurite outgrowth of nerve cells are integrin-mediated and achieved by the activation of PKC? and FAK phosphorylation. Thus, the present invention can be very useful for researches on cell adhesion, spreading, migration, and neurite outgrowth activities of cells which are focused on nerve cells and mediated by various extracellular matrix proteins including laminin, manufacture of artificial nerve conduits, burns treatment, wounds treatment, and tissue regeneration.Type: ApplicationFiled: March 12, 2012Publication date: September 20, 2012Applicant: SNU R&DB FOUNDATIONInventor: Byung-Moo MIN
-
Publication number: 20120238508Abstract: The present invention provides methods for promoting wound healing and/or reducing scar formation, by administering to an individual in need thereof one or more of the heat shock protein 20-derived polypeptides disclosed herein.Type: ApplicationFiled: January 4, 2012Publication date: September 20, 2012Inventors: Colleen BROPHY, Alyssa Panitch, Catherine Parmiter, Elizabeth Furnish, Padmini Komalavilas
-
Patent number: 8263562Abstract: The application of a peptide having sequence of formula I or its derivant in preparing the medicine for preventing or treating liver damage, especially liver damage and hepatitis C is disclosed, Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4 (formula I) wherein, Xaa1 is deletion, Ala, Gly, Val, Leu or Ile, Xaa2 is Thr or Ser, Xaa3 is Tyr, Phe or Trp, and Xaa4 is deletion, Ala, Gly, Val, Leu, Ile or Pro. The composite medicine containing the said peptide, its preparation method, and the polynucleotide for coding the said peptide are also disclosed.Type: GrantFiled: June 17, 2011Date of Patent: September 11, 2012Inventors: Yun Cheng, Ruihe Yu, Wanzhou Zhao, Jun Zhao, Jing Li
-
Patent number: 8263555Abstract: The invention provides methods for treating and/or preventing ocular disorders associated with increased intraocular pressure comprising administering a bradykinin B2 receptor agonist to a patient in need thereof.Type: GrantFiled: August 24, 2010Date of Patent: September 11, 2012Assignee: Alcon Research, Ltd.Inventor: Najam A. Sharif
-
Publication number: 20120225826Abstract: The present invention provides compositions and methods for enhancing transport of biologically active compounds across biological membranes and across and into animal epithelial or endothelial tissues. The composition includes a biologically active agent and a transport moiety. The transport moiety includes a structure selected from the group consisting of (ZYZ)nZ, (ZY)nZ, (ZYY)nZ and (ZYYY)nZ. Subunit “Z” is L-arginine or D-arginine, and subunit “Y” is an amino acid that does not comprise an amidino or guanidino moiety. Subscript “n” is an integer ranging from 2 to 10. The method for enhancing transport involves the administration of the aforementioned composition.Type: ApplicationFiled: September 29, 2011Publication date: September 6, 2012Inventors: Paul A. Wender, Jonathan B. Rothbard, Lee Wright, Erik L. Kreider, Christopher J. VanDeusen
-
Publication number: 20120225831Abstract: Melanocortin receptor-specific linear peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.Type: ApplicationFiled: May 16, 2012Publication date: September 6, 2012Applicant: PALATIN TECHNOLOGIES, INC.Inventors: Wei Yang, Yi-Qun Shi
-
Publication number: 20120219505Abstract: The present invention is directed to peptide reagents, methods for detecting colon pre-cancer (dysplasia with non-polypoid or polypoid morphology) or cancer using the peptide reagents, and methods for targeting pre-cancerous or cancerous colon cells using the peptide reagents.Type: ApplicationFiled: December 19, 2011Publication date: August 30, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Thomas D. Wang, Sharon Miller, Bishnu Joshi
-
Patent number: 8247529Abstract: The present invention provides compositions including neoplasia targeting peptides as well as methods of using the neoplasia targeting peptides in diagnosing, detecting, treating, monitoring treatment, and analyzing cancer or cancer cells in vivo and in vitro.Type: GrantFiled: May 15, 2009Date of Patent: August 21, 2012Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Thomas D. Wang, Shaoying Lu
-
Publication number: 20120201753Abstract: Disclosed are compositions and methods useful for targeting regenerating tissue, wounds, and tumors. The compositions and methods are based on peptide sequences that selectively bind to and home to regenerating tissue, wound sites, and tumors in animals. The disclosed targeting is useful for delivering therapeutic and detectable agents to regenerating tissue, wound sites, and tumors in animals.Type: ApplicationFiled: April 19, 2012Publication date: August 9, 2012Inventors: Erkki Ruoslahti, Tero Jarvinen
-
Publication number: 20120203102Abstract: This invention is directed to non-benzenoid aromatic compounds. Other aspects include methods of using non-benzenoid aromatic compounds for imaging and phototherapeutic uses thereof. Non-benzenoid compounds provided herein generally have one or more substituent groups which allow tailoring of the spectral properties or provide photoreactivity or targeting ability.Type: ApplicationFiled: September 10, 2010Publication date: August 9, 2012Applicant: MALLINCKRODT LLCInventor: Raghavan Rajagopalan
-
Patent number: 8236761Abstract: The cell surface c-Met receptor, through which hepatocyte growth factor (HGF) signals are mediated, has now been identified as the Angiotensin-IV receptor (AT(4)R) in processes that include HGF-regulated cell motility, angiogenesis, cancer metastasis, adipogenesis and others. Disclosed are angiotensin-like factor compositions and methods for using them to diagnose, prevent and/or treat conditions associated with c-Met dysregulation, including cancer, obesity and conditions associated with obesity, and other disorders, for example, by altering hepatocyte growth factor activity or c-Met receptor activity by administering an angiotensin-like factor that specifically binds to a cell surface c-Met receptor.Type: GrantFiled: January 10, 2008Date of Patent: August 7, 2012Assignee: Washington State University Research FoundationInventors: Joseph W. Harding, John W. Wright, Patrick D. Elias, Brent J. Yamamoto
-
Publication number: 20120195847Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer.Type: ApplicationFiled: September 17, 2009Publication date: August 2, 2012Applicant: Nektar TherapeuticsInventors: Yujun Wang, Ping Zhang, Mary J. Bossard, Steven O. Roczniak
-
Publication number: 20120190626Abstract: The present invention provides a peptide which functions as a mimic peptide of an amyloid ? peptide and is capable of inhibiting the fibrillogenesis of an amyloid ? peptide. The present invention relates to an 8- to 30-amino acid residue peptide comprising an amino acid sequence represented by the following formula (I): X1-Asp-X2-X3-X4-Pro-X5-X6 (SEQ ID NO: 28) (I), wherein X1 represents a branched chain amino acid, and X2, X3, X4, X5, and X6 are the same or different and each represents an ?-amino acid, and to a pharmaceutical composition and an amyloid ? fibrillogenesis inhibitor comprising the peptide.Type: ApplicationFiled: December 16, 2011Publication date: July 26, 2012Inventor: Kazuhisa SUGIMURA
-
Publication number: 20120190625Abstract: The present invention provides a peptide comprising an amino acid sequence of SEQ ID NO: 1, a variant thereof and a pharmaceutically acceptable salt thereof. A novel peptide of the present invention, a variant thereof and a pharmaceutically acceptable salt thereof are effective for treating and/or preventing degenerative disc diseases, treating body organ fibrosis, treating cancer and/or treating glomerulosclerosis, and are effective for the inhibition of TGF-beta1 signaling.Type: ApplicationFiled: February 12, 2010Publication date: July 26, 2012Applicant: ENSOLTEK CO., LTD.Inventors: Hae Jin Kim, Eun Joung Moon, Yang Seon Kim, Young Joon Kwon
-
Patent number: 8222215Abstract: The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.Type: GrantFiled: September 5, 2008Date of Patent: July 17, 2012Assignee: Provid Pharmaceuticals, Inc.Inventors: Gary Lee Olson, Charles Michael Cook, Christopher Raymond Self
-
Patent number: 8222216Abstract: It is found that a SVVYGLR peptide (SEQ ID NO: 1) can promote proliferation of mesenchymal cells such as marrow-derived mesenchymal stem cells and dental pulp cells. A carbonate apatite-collagen sponge containing the SVVYGLR peptide (SEQ ID NO: 1) is useful as a biomaterial for the regeneration of bone marrow or dental pulp. It becomes possible to provide a skeletal system biomaterial which is capable of promoting the proliferation of the mesenchymal cells and is useful as artificial bone marrow or artificial dental pulp for repairing a defect in a bone marrow tissue or a dental pulp tissue.Type: GrantFiled: August 29, 2007Date of Patent: July 17, 2012Assignees: Osaka University, Hiroshima UniversityInventors: Yoshinosuke Hamada, Nariaki Matsuura, Hiroshi Egusa, Yoshitoshi Kaneda, Masayuki Okazaki
-
Publication number: 20120172309Abstract: The present invention relates to a peptide of general formula (I): R1-(AA)n-X1-X2-Arg-Arg-Gly-X3-X4-(AA)p-R2. The present invention also relates to a cosmetic or pharmaceutical composition, containing at least one peptide of general formula (I), in a physiologically suitable medium. The present invention also relates to the use of a composition containing the peptide of general formula (I) as an active ingredient which activates human transglutaminase to reinforce the skin barrier function and to stimulate epidermal regeneration and differentiation. The invention also relates to a cosmetic treatment method for preventing and/or for combatting external stresses and signs of skin ageing.Type: ApplicationFiled: August 31, 2010Publication date: July 5, 2012Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto